What Our Investors Say
The trust of our investors is the foundation upon which XGEN VENTURE SGR SPA is built. We are grateful to those who have chosen to partner with us and who share our conviction that life sciences venture capital represents a compelling combination of financial opportunity and genuine social impact. The following testimonials reflect the experiences of qualified investors across our fund structures. We take every piece of feedback seriously as we continuously improve our investment management and investor relations capabilities.
I have been invested with XGEN VENTURE for over three years now, and the level of scientific rigour they apply to deal selection is genuinely impressive. Unlike generalist VC managers, their team clearly understands the biology behind the companies they back. The quarterly reporting is comprehensive and transparent — I always know exactly where my capital is deployed and how the portfolio is performing. It is rare to find a fund manager that combines such scientific depth with genuine fiduciary professionalism.
★★★★★
— Margherita Conti
As a family office with longstanding exposure to European private markets, we were looking for a differentiated approach to life sciences VC, and XGEN VENTURE delivered exactly that. Their investment thesis is clearly articulated, and the portfolio construction reflects genuine strategic thinking rather than opportunistic deal chasing. The co-investment access available at our commitment level has allowed us to meaningfully increase our position in two particularly promising portfolio companies. We look forward to deepening our partnership with them in future fund vintages.
★★★★★
— Thomas Brückner
We committed to the XGEN VENTURE fund as part of our institution's alternative asset allocation, with a specific focus on healthcare innovation exposure. The onboarding process was smooth and thorough, and the team took considerable time to walk us through their investment methodology and risk management framework. Eighteen months in, the portfolio is tracking well against our expectations, and the management team has been consistently accessible for questions. We appreciate the proactive communication style — it reflects a genuine respect for the investor relationship.
★★★★☆
— Isabelle Moreau-Lambert
What drew me to XGEN VENTURE was their explicit focus on the European biotech ecosystem at a time when most venture capital attention seemed concentrated in the United States. Their knowledge of the local regulatory environment, academic spinout landscape, and pharma partnership dynamics proved invaluable in understanding the portfolio. The annual investor summit is a particularly valuable touchpoint — the access to portfolio company founders and scientific advisors creates a level of insight I have not experienced with other fund managers. I would recommend XGEN VENTURE to any sophisticated investor with a genuine interest in the sector.
★★★★★
— Davide Pellegrini
I initially had questions about committing to an asset class with the inherent development timelines of life sciences VC, but the XGEN VENTURE team was patient and thorough in addressing my concerns. They were candid about the risk profile and helped me understand how their portfolio construction strategy mitigates concentration risk across development stages. The reporting and governance frameworks they operate under gave me additional confidence as a first-time alternative fund investor. I am pleased with the decision and look forward to seeing the longer-term outcomes of the portfolio.
★★★★☆
— Karolina Wiśniewska